How have the shares performed?
Enzo Biochem Inc. (ENZ) saw an uptrend of 0.31% in the recent trading with $3.20 being its most recent. The current price level -34.02% lower than the highest price of $4.85 marked by the stock while trading over the past 52-weeks, whereas it is 77.78% higher than the lowest price of $1.80 the company dropped to over past 52-weeks. The latest news story on ENZ appeared in GlobeNewswire under the title “Enzo Biochem Reports Third Quarter Fiscal 2021 Results” on Jun-09-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -4.48% below one month high and is +14.29% above of the lowest during that time. Looking into the simple moving average, Enzo Biochem Inc. (ENZ)’s stock stands at a SMA-50 of $3.18 while that of 5-day is reading $3.16.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ENZ’s SMA-200 as of now is $2.70.
Enzo Biochem Inc. Earnings – What Happened With ENZ
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $31.47 billion.
ENZ – Enzo Biochem Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 48.01 million. ENZ does have institutional investors; and they hold 57.90% of the stock.
Enzo Biochem Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, ENZ declared 144,768 shares have been sold in 2 insider transactions over the past three months.
As on Mar 30, 2021, Harbert Fund Advisors, Inc. was the top most holder in Enzo Biochem Inc. (NYSE:ENZ) with an ownership of 5.18 million shares of the company or 10.73% of the stake worth $17.81 million. The filing also reveals Blackrock Inc. as the second largest holder in the company with a control over 8.10% of the outstanding shares. Its stake is worth $13.44 million for having 3.91 million shares in hand.
Renaissance Technologies, LLC also came holding a key position in the company during the recent quarter and it now holds 6.93% of the outstanding shares. With this there are now 112 institutions which have possession in ENZ’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Enzo Biochem Inc. was 2.10 while posting a debt to equity ratio of 0.19. The count was 36.58 for long-term debt to equity ratio.
Enzo Biochem Inc.’s return on equity, or ROE, is -17.50%, compared to the industry average of 0.30% for Healthcare – Diagnostics & Research. Although this indicates that ENZ fails to use its equity well, the metric will vary significantly depending on the industry.
Technical Analysis of Enzo Biochem Inc. (NYSE:ENZ) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Enzo Biochem Inc. (ENZ), we notice that the stock’s 20-day average volume is at 318,265 shares. Medium term indicators at an average of 75% are spotting the stock at Buy with its 50-day average volume of 297,650 shares. And to end, ENZ’s 100-day average volume is 910,312 shares with 100% of the long-term indicators pointing towards Buy for the stock.